CHEMBIO DIAGNOSTICS, INC.: Nasdaq/NYSE listing notice — Chembio Diagnostics receives Nasdaq delisting notice for bid price non-compliance; plans to request hearing

CHEMBIO DIAGNOSTICS, INC.

Received formal delisting notice from Nasdaq on April 6, 2023, for continued non-compliance with minimum bid price rule.
Non-compliance first disclosed April 2022; two grace periods expired April 3, 2023 without compliance.
Intends to timely request a hearing before Nasdaq Hearings Panel to stay delisting pending decision.
No assurance that Panel will continue listing or that compliance can be achieved within any extension.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

CHEMBIO DIAGNOSTICS, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)

Exact text from the filing

April 6, 2023, Chembio Diagnostics, Inc. (the “Company”) received formal notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s continued non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a) (the “Bid Price Rule”) would result in the delisting of the Company’s securities from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company intends to timely request a hearing before the Panel, which request will stay any further a

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001140361-23-017055

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.